Edition:
United Kingdom

Athersys Inc (ATHX.OQ)

ATHX.OQ on NASDAQ Stock Exchange Capital Market

1.80USD
24 May 2019
Change (% chg)

$-0.06 (-3.23%)
Prev Close
$1.86
Open
$1.87
Day's High
$1.92
Day's Low
$1.79
Volume
103,928
Avg. Vol
137,584
52-wk High
$3.08
52-wk Low
$1.36

Latest Key Developments (Source: Significant Developments)

Athersys Q4 Earnings Per Share Estimate $-0.08 -- Refinitiv Ibes Data
Thursday, 14 Mar 2019 

March 14 (Reuters) - Athersys Inc ::ATHERSYS ANNOUNCES FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2018.Q4 LOSS PER SHARE $0.08.Q4 REVENUE $1.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $1.5 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.08 -- REFINITIV IBES DATA.ENDED 2018 WITH $51.1 MILLION IN CASH AND CASH EQUIVALENTS.AT FEB 2019 END, CO HAD $51.5 MILLION IN CASH AND CASH EQUIVALENTS.  Full Article

Athersys Announces Results From Exploratory Clinical Study Of Multistem Cell Therapy For Acute Respiratory Distress Syndrome
Wednesday, 23 Jan 2019 

Jan 23 (Reuters) - Athersys Inc ::ATHERSYS ANNOUNCES POSITIVE RESULTS FROM ITS EXPLORATORY CLINICAL STUDY OF MULTISTEM® CELL THERAPY FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS).ATHERSYS INC - WILL CONTINUE TO EVALUATE DATA AS ONE-YEAR FOLLOW-UP PERIOD IS COMPLETED FOR ALL PATIENTS IN TRIAL FOR MULTISTEM.ATHERSYS - ENDED YEAR WITH ABOUT $51 MILLION IN CASH AND CASH EQUIVALENTS.ATHERSYS INC - LOWER MORTALITY OF 25% IN MULTISTEM TREATMENT GROUP VERSUS. 40% IN PLACEBO GROUP FOR MULTISTEM.  Full Article

Healios To Make Payment To Extend Exclusive Period For Negotiating Option For License To Multistem Therapy For Indications In China
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Athersys Inc ::HEALIOS AGREES TO MAKE PAYMENT TO EXTEND EXCLUSIVE PERIOD FOR NEGOTIATING AN OPTION FOR A LICENSE TO MULTISTEM® THERAPY FOR INDICATIONS IN CHINA.ATHERSYS INC - HEALIOS HAS AGREED TO MAKE A ONE-TIME $2.0 MILLION PAYMENT IN DECEMBER 2018 FOR AN EXTENSION THROUGH JUNE 30, 2019.ATHERSYS INC - HEALIOS MAY MAKE ADDITIONAL PAYMENT OF $3.0 MILLION TO EXTEND NEGOTIATION PERIOD THROUGH DEC31, 2019.ATHERSYS - PAYMENTS BY HEALIOS WOULD BE CREDITABLE AGAINST $15 MILLION OPTION FEE THAT WOULD BE PAYABLE UPON EXECUTION OF CHINA OPTION AGREEMENT.  Full Article

Athersys And Healios Extend By One Month The Period To Complete Collaboration Expansion Agreements
Tuesday, 1 May 2018 

May 1 (Reuters) - Healios KK <4593.T>::ATHERSYS AND HEALIOS EXTEND BY ONE MONTH THE PERIOD TO COMPLETE COLLABORATION EXPANSION AGREEMENTS.ATHERSYS INC - CO, HEALIOS K.K. AGREED TO EXTEND PERIOD FROM APRIL 30, 2018 TO MAY 31, 2018.  Full Article

Athersys reports Q3 loss per share $0.06
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Athersys Inc :Athersys reports third quarter 2017 results.Q3 loss per share $0.06.Q3 revenue $400,000 versus $300,000.Q3 revenue view $598,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.  Full Article

Athersys and Nikon Cell Innovation to collaborate on MultiStem manufacturing in Japan
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Athersys Inc ::Athersys and Nikon Cell Innovation to collaborate on multistem commercial manufacturing in Japan.Athersys - entered manufacturing services agreement with Nikon Cell for commercial production of its stem cell therapy in Japan for ischemic stroke.Athersys - technology transfer of stem cell production methods in preparation for potential commercialization in Japan after treasure clinical study.  Full Article